NKLRB1 (CD161), a lectin C-type inhibitory receptor, has also been considered as a possible immune checkpoint, as it recognizes the lectin-like transcript 1 (LLT1) that is expressed by some tumors, such as B cell non-Hodgkin lymphoma. The gene discussed is CLEC2D; the disease is B-cell non-Hodgkin lymphoma.